12 September 2022 : Editorial
Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
DOI: 10.12659/MSM.938365
Med Sci Monit 2022; 28:e938365